SRPT

+ Watchlist + Portfolio

Sarepta Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $19.73
52-Week Range: $14.68 – $25.32
Market Cap: $2.03B
P/E (TTM): —
EPS (TTM): -1.57
Dividend Yield: —

Advanced Metrics

Price/Book: 1.33
PEG Ratio: -0.09
Return on Equity: -9.48%
Return on Assets: -1.13%
Gross Margin: -17.30%
Operating Margin: 13.03%
Profit Margin: -6.93%
Current Ratio: 4.42
Debt/Equity: 0.70
Total Debt: $1.06B
Free Cash Flow: $22.14M
Revenue Growth: -34.30%
Earnings Growth: —
Enterprise Value: $2.30B

SRPT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$933.01M	$1.24B	$1.90B	$2.20B
Cost of Revenue	$139.99M	$150.34M	$319.10M	$839.61M
Gross Profit	$793.02M	$1.09B	$1.58B	$1.36B
Research & Development	$877.09M	$877.39M	$804.52M	$1.52B
Selling, General & Admin	$451.42M	$481.87M	$557.87M	$491.72M
Operating Expenses	$1.33B	$1.36B	$1.36B	$2.02B
Operating Income	-$536.20M	-$267.82M	$218.08M	-$657.77M
EBITDA	-$594.85M	-$453.69M	$316.89M	-$619.56M
Pretax Income	-$689.96M	-$520.10M	$260.77M	-$702.23M
Income Tax	$13.53M	$15.88M	$25.54M	$11.19M
Net Income	-$703.49M	-$535.98M	$235.24M	-$713.41M
Diluted EPS	-8.03	-5.80	2.34	-7.13
Diluted Shares	87.56M	92.40M	107.88M	97.49M

SRPT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$966.78M	$428.43M	$1.10B	$801.28M
Receivables	$261.60M	$436.98M	$651.70M	$519.61M
Inventory	$203.97M	$322.86M	$749.96M	$914.74M
Current Assets	$2.56B	$2.58B	$3.07B	$2.54B
Total Assets	$3.13B	$3.26B	$3.96B	$3.35B
Current Liabilities	$619.60M	$653.66M	$731.68M	$1.10B
Long-Term Debt	$1.54B	$1.13B	$1.14B	$828.97M
Total Debt	$1.62B	$1.40B	$1.34B	$1.04B
Total Liabilities	$2.74B	$2.41B	$2.44B	$2.21B
Retained Earnings	-$3.91B	-$4.45B	-$4.21B	-$4.88B
Shareholders' Equity	$384.95M	$859.34M	$1.53B	$1.14B
Working Capital	$1.94B	$1.93B	$2.34B	$1.44B
Net Debt	$577.51M	$809.57M	$34.11M	$27.69M

SRPT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$325.35M	-$500.99M	-$205.79M	-$205.48M
Capital Expenditure	-$32.25M	-$87.34M	-$146.96M	-$109.85M
Free Cash Flow	-$357.60M	-$588.34M	-$352.74M	-$315.33M
Depreciation & Amortisation	$41.86M	$44.40M	$37.72M	$44.52M
Stock-Based Compensation	$233.02M	$182.51M	$184.30M	$123.40M
Investing Cash Flow	-$1.05B	-$165.80M	$755.56M	$69.64M
Financing Cash Flow	$232.51M	$125.00M	$124.81M	-$168.34M
Share Repurchases	—	$0.00	$0.00	-$25.01M
Net Change in Cash	-$1.14B	-$541.79M	$674.58M	-$304.18M

SRPT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$744.86M	$611.09M	$399.36M	$442.93M	$730.80M
Cost of Revenue	$137.56M	$152.56M	$150.78M	$398.71M	$108.77M
Gross Profit	$607.29M	$458.53M	$248.58M	$44.23M	$622.03M
Research & Development	$773.45M	$204.39M	$218.89M	$325.34M	$153.96M
Selling, General & Admin	$133.63M	$137.90M	$91.89M	$128.30M	$108.95M
Operating Expenses	$907.68M	$342.96M	$311.46M	$454.31M	$263.60M
Operating Income	-$300.39M	$115.58M	-$62.88M	-$410.08M	$358.43M
EBITDA	-$369.04M	$169.71M	-$168.03M	-$252.20M	$375.48M
Pretax Income	-$383.52M	$153.64M	-$194.05M	-$278.30M	$343.17M
Income Tax	$63.99M	-$43.25M	-$14.10M	$4.55M	$12.21M
Net Income	-$447.51M	$196.89M	-$179.95M	-$282.85M	$330.96M
Diluted EPS	-4.60	1.89	-1.80	-3.93	2.88
Diluted Shares	97.36M	106.62M	100.24M	104.79M	121.92M

SRPT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$240.87M	$510.60M	$613.08M	$801.28M	$464.45M
Receivables	$724.52M	$609.60M	$541.60M	$519.61M	$547.91M
Inventory	$941.43M	$994.04M	$1.08B	$914.74M	$1.00B
Current Assets	$2.43B	$2.66B	$2.72B	$2.54B	$2.31B
Total Assets	$3.47B	$3.68B	$3.49B	$3.35B	$3.18B
Current Liabilities	$605.59M	$919.95M	$921.42M	$1.10B	$499.16M
Long-Term Debt	$1.14B	$1.14B	$1.04B	$828.97M	$838.16M
Total Debt	$1.34B	$1.35B	$1.25B	$1.04B	$1.04B
Total Liabilities	$2.32B	$2.32B	$2.17B	$2.21B	$1.67B
Retained Earnings	-$4.66B	-$4.46B	-$4.64B	-$4.88B	-$4.55B
Shareholders' Equity	$1.14B	$1.36B	$1.32B	$1.14B	$1.51B
Working Capital	$1.83B	$1.74B	$1.80B	$1.44B	$1.81B
Net Debt	$897.42M	$628.86M	$422.07M	$27.69M	$373.71M

SRPT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$583.44M	$261.34M	-$14.59M	$131.21M	-$202.68M
Capital Expenditure	-$45.89M	-$31.98M	-$28.25M	-$3.73M	-$3.08M
Free Cash Flow	-$629.33M	$229.35M	-$42.83M	$127.48M	-$205.76M
Depreciation & Amortisation	$9.98M	$10.84M	$18.45M	$5.25M	$10.59M
Stock-Based Compensation	$41.43M	$37.02M	$14.93M	$30.02M	$29.40M
Investing Cash Flow	-$291.18M	$32.21M	$232.40M	$96.21M	-$134.39M
Financing Cash Flow	$12.47M	-$23.82M	-$117.79M	-$39.21M	$241.00K
Share Repurchases	—	—	$0.00	$0.00	—
Net Change in Cash	-$862.14M	$269.73M	$100.03M	$188.21M	-$336.83M

Market Snapshot

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on precision genetic medicine for rare diseases. The company develops RNA-targeted therapeutics and gene therapy candidates, particularly for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies. It has multiple approved treatments and a robust pipeline of investigational therapies.